Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma

NCT00972686 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00972686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00972686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2009
Completion date
March 31, 2015
Enrollment
79 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumours